Skip to main content
See every side of every news story
Published loading...Updated

New drug combination could delay the progression of advanced prostate cancer

The Phase III AMPLITUDE trial showed niraparib with standard therapy reduced cancer growth risk by 37% overall and 48% in patients with BRCA1/BRCA2 mutations.

Summary by Medical Xpress
A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with specific genetic mutations, finds a major international trial led by UCL researchers.

6 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 67% of the sources are Center
67% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Medical Xpress broke the news in on Tuesday, October 7, 2025.
Sources are mostly out of (0)

Similar News Topics

News
For You
Search
BlindspotLocal